Agonist News and Research

RSS

Long-term alcohol use changes brain functions differently in young men and women

Scientists have found that brain functions in young men and women are changed by long-term alcohol use, but that these changes are significantly different in men and women.

4 Sep 2017

Common obesity and diabetes drug could be used as novel way to lower brain pressure

Research led by the University of Birmingham, published today in Science Translational Medicine, has discovered that a drug commonly used to treat patients with either obesity or Type II diabetes could be used as a novel new way to lower brain pressure.

23 Aug 2017

Diabetes drug shows promise as Parkinson’s treatment

A drug commonly used to treat diabetes could help people living with Parkinson’s disease, say researchers.

7 Aug 2017

New drug may limit disease progression, provide better symptom relief to Parkinson's patients

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

31 Jul 2017

Small-molecule drug improves brain performance in mouse model of Rett syndrome

After learning that a small-molecule drug improves breathing in a mouse model of the neurodevelopmental disorder Rett syndrome, University of Alabama at Birmingham researcher Lucas Pozzo-Miller, Ph.D., wondered if he could test it on other brain functions.

28 Jul 2017

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Researchers from the University of Southampton have identified why some people may become resistant to monoclonal antibodies, a common type of immunotherapy used in lymphoma treatment.

17 Jul 2017

New study links hepatic inflammation to western diet

A new study in The American Journal of Pathology reports that mice fed a Western diet, which is high in fat and sugar, resulted in hepatic inflammation, especially in males. Moreover, liver inflammation was most pronounced in Western diet-fed male mice that also lacked farnesoid x receptor (FXR), a bile acid receptor.

12 Jul 2017

Study opens new range of therapeutic options for patients with atypical Rett syndrome

A translational, multicenter study carried out by research groups of the Bellvitge Biomedical Research Institute, San Juan de Dios Hospital, the University of Barcelona, Clinic Hospital, the University of Vic, Santa Creu i Sant Pau Hospital and the thematic area of Rare Diseases, has unveiled the potential of D-serine -- a dietary supplement -- to improve the neuronal function of a patient with a mutation of the glutamate receptors associated to atypical Rett syndrome with severe encephalopathy.

4 Jul 2017

Review highlights effective treatment options for managing patients with T2D and osteoporosis

Type 2 diabetes (T2D) and osteoporosis often coexist in patients, but managing both conditions can be a challenge.

21 Jun 2017

Anti-nausea drug may be new treatment for obstructive sleep apnea

An old pharmaceutical product may be a new treatment for obstructive sleep apnea, according to new research presented today by University of Illinois at Chicago and Northwestern University scientists at the SLEEP 2017 annual meeting in Boston.

6 Jun 2017

Research findings may pave way for miracle drug to treat narcolepsy

Narcolepsy, a serious sleep disorder in which patients often fall asleep uncontrollably, has been incurable because no effective therapeutic agents are available to date. Recent findings by Japanese scientists in the sleep institute may shed light on this challenging problem.

30 May 2017

Investigational biologic may reduce need for systemic corticosteroids in patients with severe asthma

An investigational biologic may reduce the need for adults with severe asthma to take an oral corticosteroid to control their asthma, according to a randomized controlled trial presented at the ATS 2017 International Conference.

22 May 2017

Breast cancer drug offers protection against obesity-related metabolic disorders

Tamoxifen, a selective estrogen receptor modulator, is the gold standard for endocrine treatment of estrogen-receptor positive breast cancer.

11 May 2017

Texas A&M researchers aim to develop one drug that treats pain, memory and nicotine addiction

Although pain, memory and nicotine addiction may not seem to be related, they actually share a common player: the nicotinic acetylcholine receptors.

5 May 2017

Powerful pain medicine may help reduce vision damage of glaucoma

The tip of our optic nerve is typically the first place injured by glaucoma. Now researchers want to know if the powerful pain medicine (+)-pentazocine can help avoid the damage.

2 May 2017

Synthetic scaffold loaded with cancer-fighting T cells effectively shrinks solid tumors

Cellular therapy hasn't had much success in fighting solid tumors, partly because it's been difficult to deliver anti-cancer T cells to the tumors.

25 Apr 2017

Researchers develop new approach to protect stem cell recipients from graft-versus-host disease

Stem cell transplants can save lives, for example in patients with leukemia. However, these treatments are not free of risks. One complication that may occur is graft-versus-host disease (GVHD), basically donor-derived immune cells attacking the recipient’s body.

21 Apr 2017

Medication-assisted treatment reduces negative health outcomes for pregnant women with OUD

Medication for addiction treatment (MAT) with buprenorphine or methadone is an appropriate and accepted treatment for pregnant women with opioid use disorder (OUD), according to a research review and update in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published by Wolters Kluwer.

17 Apr 2017

Study reveals that 25% of women with prenatal opioid addiction are not being treated

A new study by Queen's University researcher Susan Brogly (Surgery) has revealed that 25 per cent of women suffering from a prenatal opioid dependence were not being treated for their addiction.

5 Apr 2017

MSU and Venn Therapeutics develop promising therapy to delay B16 melanoma tumor growth

Michigan State University researchers presented promising cancer therapy results at the American Association for Cancer Research International Meeting in Washington, DC.